Navigation Links
Yondelis(R) Sales Expanded by 70 Percent
Date:10/28/2010

MADRID, Oct. 28 /PRNewswire/ -- Group revenues totaled 120 million euro (approximately 167 million USD*) in the first nine months of 2010, i.e. an increase of 26.1 percent with respect to the same period last year (95.19 million euro or approximately 132.6 million USD).

Net sales in the Biopharmaceutical business amounted to 56.9 million euro or approximately 79.3 million USD (35.8 million euro or approximately 49.9 million USD in the first nine months of 2009), of which 51.8 million (approximately 72.1 million USD) correspond to Yondelis sales (30.4 million euro or approximately 42.3 million USD in 9M09). Genomica's sales totaled 5.1 million euro (approximately 7.1 million USD).

The Consumer chemicals division reported sales of 62.2 million euro or approximately 86.6 million USD (58.6 million euro or approximately 81.6 million USD in 9M09). This division accounted for 51.8 percent of total group revenues in the first nine months of 2010 (61.5 percent in 9M09).

The Group maintained positive EBITDA of 2.7 million euro (approximately 3.8 million USD) in 9M10, driven by steadily rising sales since the beginning of the year.

Net income attributable to the parent company improved 63 percent with respect to September 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a ch
'/>"/>

SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
2. Decision Resources Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
3. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
4. Assured Pharmacy Reports Same Store Sales for the Month of September 2010
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
6. Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010
7. Reportlinker Adds Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies Adoption of New Sales Models and Technologies
8. Gerresheimer Reports Strong Earnings and Sales Growth
9. Nonin Medical, Inc. Announces Capnography Division Name Change; Expands Swedish Manufacturing Facility to Become Full-Franchise European Sales, Distribution and Service Center
10. Health Strategies Group Introduces New One-Stop Suite of Intelligence Services for Optimizing Marketing and Sales Resources in the Institutional Channel
11. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Electrophysiologist Kevin Makati, ... traveled to Boston, MA ... 2015 Heart Rhythm Society conference. These scientific sessions ... on the ideas, people and technology that propel ... a hybrid, minimally invasive cardiac operation that combines ...
(Date:5/22/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development ... announced that J.J. Finkelstein , chief executive officer ... at two upcoming investor conferences. Mr. ... Annual Microcap Conference on Thursday May 28, 2015 in ... am EDT.  A webcast will be available at the ...
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... the results of the Company,s 72-patient, placebo-controlled Phase ... for the treatment of dry eye patients using ... model.  The exploratory study was completed in late ... by the Company in a press release, identify ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... June 11, 2007-Sugammadex - the novel,selective relaxant binding ... business unit of Akzo Nobel - demonstrated in,a ... reversal of,neuromuscular blockade as compared to neostigmine, without ... of,muscle relaxation.1, 2 The results of this pivotal ...
... Md., June 11, 2007--A team of researchers at the,National ... (NIH), has uncovered a set of genes that are ... blood vessels that feed,tumors in mice and humans. These ... targets for novel drugs that,could selectively cut off a ...
Cached Medicine Technology:Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 3NCI Researchers Discover Genes That Are Turned on at High Levels in,Tumor-associated Blood Vessels of Mice and Humans 2NCI Researchers Discover Genes That Are Turned on at High Levels in,Tumor-associated Blood Vessels of Mice and Humans 3
(Date:5/22/2015)... May 22, 2015 Combination therapy, ... option for chronic obstructive pulmonary disorder (COPD) as ... and AstraZeneca plc as well as Germany’s Boehringer ... and position. But will market payers, clinicians and ... well-entrenched products to completely new ones? , In ...
(Date:5/22/2015)... Massachusetts (PRWEB) May 22, 2015 ... is a difficult process. Historically providers have not ... by payers. Starting in 2015, Medicare has paved ... coordination activities. Thanks to the launch of ... providers and health systems using the platform will ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 ... Health IT solutions, announced today that Bill Lane, ... is the developer of BlueEHS,a first of its ... offers a customizable Electronic Health Records (EHR) with ... interfaces, a telemedicine-enabled comprehensive patient portal, and more. ...
(Date:5/22/2015)... VA (PRWEB) May 22, 2015 sweetFrog Enterprises, ... location in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog ... yogurt chain was listed as #22 on the Inc. 500 ... “I have lived and worked in East Texas for 20 ... Brad Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog ...
(Date:5/22/2015)... In an effort to support the athletes of ... donate $5 dollars for every maintenance call, and $25 ... system. Customers have their needs serviced, and donations contributed ... the Special Olympics receives money. Hence the name Everybody ... million athletes, and boasts a myriad of events. This ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... May 21 This year 28 students in 17 states ... sponsored by the Centers for Disease Control and Prevention and ... invites fifth- and sixth-grade students to create posters that encourage ... and the diseases they can cause. Downloadable files of the ...
... 21 For the second year in a row, the ... blood through the Red Cross by joining Red Cross ... Racing is a program designed to increase the number ... Participants of this program can get points for a variety ...
... quarter of those seeking treatment are addicted to the ... -- More pregnant women in drug treatment programs are ... new research shows. , The number of expectant mothers ... 2006. In 1994, methamphetamine use accounted for 8 percent ...
... "Stem cell research and regenerative medicine are in an ... very fast and many companies are being formed and ... Jonas Frisn. , As an example, a first-in-human study ... drug product, sNN0031, from the Swedish company NeuroNova. The ...
... May 21 Three HealthEast hospitals in the ... the federal government a total of $2.28 million ... Medicare fraud involving a certain type of spinal ... first hospitals to settle charges stemming from a ...
... researchers have found that bipolar disorder is more costly ... or coronary artery disease. These findings are based on ... costs (the costs of seeing any specialist and all ... of this review are being presented today at the ...
Cached Medicine News:Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 2Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:Methamphetamine Use Triples Among Pregnant Rehab Patients 2Health News:Methamphetamine Use Triples Among Pregnant Rehab Patients 3Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 2Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 3
... glass (1.5x) Gonio lens will enable visualization ... 4 mirror lens is the industry preferred ... and features : , Crispest, clearest ... previously unattainable with Gonio lenses., 4 equally ...
Onyx Liquid Embolic System is a device utilized for the pre-surgical embolization of arteriovenous malformations (AVMs)....
... to bulky biometry devices that have dominated ... is the world's only battery-operated, fully portable ... market today. Each unit weighs a mere ... multiple functions, namely: auto data capture, advanced ...
... The PalmScan P2000 Pachymeter [i.e., PalmScan ... portable,battery operated biometer, which incorporates A-mode ... used to accurately measure the corneal ... human eyes. PalmScan P2000 includes two ...
Medicine Products: